Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma	Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, primary cutaneous T-cell lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma	Recruiting	Phase 1	2026-10-05		NCT04234048

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
SciTech Development, Inc.	2

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Barbara Ann Karmanos Cancer Institute Wayne State University	Detroit	United States	1
City of Hope Medical Foundation	Duarte	United States	1
Columbia University	New York	United States	154
Mayo Clinic Arizona	Scottsdale	United States	34
Northwestern University, Robert H. Lurie Comprehensive Cancer Center	Chicago	United States	1
The University of Texas MD Anderson Cancer Center	Houston	United States	207
University of Colorado Anschutz Medical Campus	Aurora	United States	142
University of Michigan	Ann Arbor	United States	538
University of Pittsburgh Medical Center (UPMC)	Pittsburgh	United States	2
University of Southern California	Los Angeles	United States	12